Information Provided By:
Fly News Breaks for February 9, 2016
DEPO
Feb 9, 2016 | 05:40 EDT
UBS analyst Ami Fadia started Depomed with a Buy rating and $22 price target. The analyst believes the company's Nucynta franchise has a higher peak sales potential that current consensus expectations.
News For DEPO From the Last 2 Days
There are no results for your query DEPO